NAMPT and NAD+ in health and disease: emerging perspectives from molecular mechanisms to therapeutic strategies
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD⁺) salvage pathway and a key regulator of cellular energy metabolism, redox homeostasis, stress responses, and NAD⁺-dependent signaling. Through its intracellular form iNAMPT, NAMPT sustains NAD⁺ production and the activity of enzymes such as sirtuins, PARPs, and CD38; its extracellular form eNAMPT has also been implicated in interorgan communication and inflammatory signaling. Here, we review the molecular basis of the NAMPT–NAD⁺ axis, including NAD⁺ biosynthetic pathways, subcellular compartmentalization, circadian regulation, and the distinct proposed functions of iNAMPT and eNAMPT. We then evaluate its physiological and pathological roles in metabolic disorders, liver diseases, cancer, inflammatory and cardiovascular conditions, and neurodegenerative diseases. Current evidence supports a context-dependent role for NAMPT: reduced NAMPT activity and NAD⁺ depletion may contribute to metabolic dysfunction, tissue injury, and neuronal vulnerability, whereas elevated NAMPT activity can promote tumor metabolic fitness and inflammatory responses. However, NAMPT expression alone does not reliably indicate NAD⁺ pathway dependence, because outcomes are influenced by tissue context, disease stage, NAD⁺ consumption, precursor availability, and NAPRT-mediated metabolic bypass. Therapeutically, NAD⁺ precursors, NAMPT activation, and indirect modulators may be relevant in selected degenerative and metabolic settings, whereas NAMPT inhibitors remain under investigation for cancer. Their translation is limited by systemic NAD⁺ depletion, hematological and gastrointestinal toxicity, pharmacokinetic constraints, and tumor heterogeneity. Future progress will require tissue-selective modulation, direct pharmacodynamic monitoring, and biomarker-guided patient stratification.
Authors
- Xiaoliang Deng (ORCID: https://orcid.org/0009-0004-2908-7303)
- Tao Wu (ORCID: https://orcid.org/0000-0003-1567-1512)
- Chang Liu (ORCID: https://orcid.org/0000-0003-0776-6984)
- Lin Wang
- Junming Chen
- Yanqun Luo
- Lei Wang
- Yi Su
- Xiangmin Deng
Institutions
- Fudan University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Molecular Biomedicine
- Published
- 2026-11-22
- DOI
- https://doi.org/10.1186/s43556-026-00666-3
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00